GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Antibody
Comment: Zadoprubart is the INN for an anti-B and T lymphocyte attenuator (BTLA) monoclonal antibody. IMGT associate the INN with AnaptysBio clinical research code ANB032.
|
| No information available. |
Summary of Clinical Use  |
| A phase 2 study investigating ANB032 as a teatment for atopic dermatitis/eczema was terminated. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05935085 | This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD). | Phase 2 Interventional | AnaptysBio, Inc. | ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis. Lack of efficacy led to termination of ANB032 development. | |
